Horizon Biotechnology Fund

ISIN
LU1984712759

NAV
SGD 14.99
As of 28/10/2020

1-Day Change
SGD -0.33 (-2.15%)
As of 28/10/2020

Overview

INVESTMENT OBJECTIVE

The Fund aims to provide capital growth over the long term.

More

The Fund invests at least 80% of its assets in shares (equities) and equity-related securities of companies, which are biotechnology or biotechnology-related, in any country.

Less

Note: You should not make investment decisions based solely on marketing materials. You should read the Prospectus and the Product Highlights Sheet of the Fund for more details of the investment risks and seek independent professional advice where appropriate.

ABOUT THIS FUND

  • Invests globally in companies strategically aligned with environmental and social megatrends: climate change, resource constraints, growing populations, and ageing populations
  • Avoids investing in fossil fuels and companies that stand to be disrupted by the transition to a low-carbon economy
  • Experienced team of global equity investors employing a long-term approach and disciplined fundamental analysis

PORTFOLIO MANAGEMENT

Andy Acker, CFA

Global Life Sciences | Portfolio Manager

Industry since 1996. Joined Firm in 1999.

Daniel Lyons, PhD, CFA

Portfolio Manager | Research Analyst

Industry since 2000. Joined Firm in 2000.

Performance

This section is in development. Please refer to the Factsheet link at the top of this page for fund performance.

ANNUAL FEES & EXPENSES (As of Fiscal Year End, 31/12/2019)
Initial Charge 5.00%
Annual Charge 1.20%
Ongoing Charge
(As of 31/12/2019)
2.11%
Performance Fee 20% of the 'Relevant Amount'

Portfolio

Top Holdings (As of 30/09/2020)
% of Fund
Ascendis Pharma 3.68
Sarepta Therapeutics 3.36
FORMA Therapeutics 2.86
Neurocrine Biosciences 2.69
Horizon Therapeutics 2.55
Cardiff Oncology 2.33
Akero Therapeutics 2.31
BioMarin Pharmaceutical 2.23
Essa Pharma 2.23
Alexion Pharmaceuticals 2.19

Documents

TOP